INTRODUCTION
The search for ways to accelerate new bone formation is a constant in the medical and dental areas. Thus, there has been researched on the influence of blood cells on biomaterials applied in the human body. This evolution stems from the late 1990s in the last century, with the release of platelet-rich plasma (PRP)1, followed by the second generation of platelet aggregates, platelet-rich fibrin (PRF)2, until the recent advanced platelet-rich fibrin clot (a-PRF)3.
These platelet concentrates propose an acceleration in healing of soft and hard tissues by increasing the concentration of growth factors such as transforming growth factor-b (TGF-b), insulin-like growth factor-1 (IGF-1), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), epidermal growth factor (EGF) and platelet-derived epidermal growth factor (PDEGF)4-6.
The use of platelet aggregates in injectable form is widespread, especially in orthopedics6 and in plastic surgery7, where it was possible to obtain favorable results, but these concentrates use venous blood collection tubes with anticoagulants or separating gel. However, the tubes used in the technique to be presented in this work have no additives that interfere in the process.
Thus, the objective of this technical note is to present a platelet-rich fibrin production alternative for use in liquid (injectable) or polymerized (clot) forms.
I-PRF OBTAINING METHOD
To obtain the i-PRF, blood collection was performed using 9 ml tubes without any additive (Dry Vacutube, Biocon®, Brazil). The blood used for making the i-PRF was donated by the researchers themselves. After collecting three tubes, they were placed in the horizontal centrifuge (B-40, RDE®, Brazil), with a tube filled with water in order to maintain the balance during centrifuging for two minutes at 3300 rpm. Upon termination of this process, it is possible to observe an orange color area in the tube (i-PRF) and the remaining blood materials below (Figure 1). Then, the tubes were opened carefully, to avoid homogenization of the material. We collected 5 ml of i-PRF (Figure 3) from the tubes (Figure 2) using a 20ml syringe (Injex®, Brazil) with a 18G hypodermic needle (Injex®, Brazil).
I-PRF AGGLUTINATION WITH BONE GRAFT
To demonstrate the i-PRF agglutination and to quantify its polymerization time we employed a hydroxyapatite particulate bone graft (Alobone, Osseocon®, Brazil). To prepare this mixture, we used a metal tank for arranging the i-PRF (Figure 4). After five minutes we gradually added bone graft particles (Figure 5). Within 15 minutes, it is possible to observe the start of polymerization, the material being ready for use in total time of 20 minutes, and can be removed to perform the bone grafting (Figure 6).
DISCUSSION
Obtaining i-PRF was only possible by use of tubes for blood collection without additives, different from the tubes with clot activators commonly used for the analysis of blood chemistry and in making the PRF8. Prior to completion of the technique, tests were conducted with this tube, which contains silica in its walls (clot activator), its presence having been already analyzed, showing no cytotoxic effect9. With this test, we obtained a fibrin clot in a short centrifugation time, only one minute, using the same spin speed used in the presented method. The blood collection tubes used to obtain i-PRF corroborate the same as described in other studies2,3,7,8, not using anticoagulants, present in other techniques for making platelet aggregates1,10.
The i-PRF is a new alternative to the platelet aggregate to different areas of Medicine and Dentistry, enabling experts to further research this product. Because it is autogenous, it decreases the chances of adverse reactions to the implanted material, especially immune-mediated ones, as with other types of grafting11, which qualifies it as a viable option in regenerative procedures.
The possibility of bonding of i-PRF with biomaterials for bone grafting creates an alternative to PRP as a platelet aggregate for bone regeneration. PRP is used in regenerative procedures because of the possibility to optimize bone formation12. The technique presented in this study permits incorporation of the graft without the use of anticoagulants or other additives, thereby forming a well-agglutinated "steak for bone grafting", as shown.
We believe that, with this technique, physicians and dentists may carry out different studies, quickly and simply providing i-PRF for use in liquid or polymerized form.